Search

Your search keyword '"Geurtsvankessel, Corine"' showing total 636 results
Start Over Author "Geurtsvankessel, Corine"
636 results on '"Geurtsvankessel, Corine"'

1. Molecular characterisation of human rabies in Tanzania and Kenya: a case series report and phylogenetic investigation

Author

Jaswant, Gurdeep, Campbell, Kathryn, Czupryna, Anna, Mwatondo, Athman, Ogoti, Brian, Embregts, Carmen W. E., GeurtsvanKessel, Corine H., Kayuki, Charles, Kuchaka, Davis, Wambura, Gati, Oigo, James, Changalucha, Joel, Oyugi, Julius O., Lushasi, Kennedy, Sikana, Lwitiko, van Zwetselaar, Marco, Dekker, Marieke C. J., Muturi, Mathew, Maritim, Marybeth, Mutunga, Mumbua, Durrant, Rowan, Abala, Tom, Chuchu, Veronicah, Brunker, Kirstyn, Thumbi, S. M., and Hampson, Katie

Published
2024
Full Text
View/download PDF

3. Author Correction: Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients

Author

Millat-Martinez, Pere, Gharbharan, Arvind, Alemany, Andrea, Rokx, Casper, Geurtsvankessel, Corine, Papageorgiou, Grigorios, van Geloven, Nan, Jordans, Carlijn, Groeneveld, Geert, Swaneveld, Francis, van der Schoot, Ellen, Corbacho-Monné, Marc, Ouchi, Dan, Piccolo Ferreira, Francini, Malchair, Pierre, Videla, Sebastian, García García, Vanesa, Ruiz-Comellas, Anna, Ramírez-Morros, Anna, Rodriguez Codina, Joana, Amado Simon, Rosa, Grifols, Joan-Ramon, Blanco, Julian, Blanco, Ignacio, Ara, Jordi, Bassat, Quique, Clotet, Bonaventura, Baro, Bàrbara, Troxel, Andrea, Zwaginga, Jaap Jan, Mitjà, Oriol, and Rijnders, Bart J. A.

Published
2024
Full Text
View/download PDF

4. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters

Author

Zaeck, Luca M., Tan, Ngoc H., Rietdijk, Wim J. R., Geers, Daryl, Sablerolles, Roos S. G., Bogers, Susanne, van Dijk, Laura L. A., Gommers, Lennert, van Leeuwen, Leanne P. M., Rugebregt, Sharona, Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Dalm, Virgil A. S. H., Lafeber, Melvin, Kootstra, Neeltje A., Huckriede, Anke L. W., Haagmans, Bart L., van Baarle, Debbie, Koopmans, Marion P. G., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., and de Vries, Rory D.

Published
2024
Full Text
View/download PDF

5. Revealing the significance of IL-2 and IL-5 in SARS-CoV-2-specific T-cell responses in kidney transplant recipients

Author

den Hartog, Yvette, Malahe, S. Reshwan K., Rietdijk, Wim J. R., Dieterich, Marjolein, Gommers, Lennert, van Baarle, Debbie, Diavatopoulos, Dimitri A., Messchendorp, A. Lianne, van der Molen, Renate G., Remmerswaal, Ester B. M., Bemelman, Frederike J., Kho, Marcia M. L., GeurtsvanKessel, Corine H., Koopmans, Marion P. G., Gansevoort, Ron T., Hilbrands, Luuk B., Sanders, Jan-Stephan, Reinders, Marlies E. J., Baan, Carla C., and de Vries, Rory D.

Published
2024
Full Text
View/download PDF

8. Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants

Author

Fryer, Holly A., Geers, Daryl, Gommers, Lennert, Zaeck, Luca M., Tan, Ngoc H., Jones-Freeman, Bernadette, Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Hogarth, P. Mark, Koopmans, Marion P.G., GeurtsvanKessel, Corine H., O’Hehir, Robyn E., van der Kuy, P. Hugo M., de Vries, Rory D., and van Zelm, Menno C.

Published
2024
Full Text
View/download PDF

10. Seroprevalence of SARS-CoV-2 antibodies among healthcare workers in Dutch hospitals after the 2020 first wave: a multicentre cross-sectional study with prospective follow-up

Author

Recanatini, Claudia, GeurtsvanKessel, Corine H., Pas, Suzan D., Broens, Els M., Maas, Martje, van Mansfeld, Rosa, Mutsaers-van Oudheusden, Anne J. G., van Rijen, Miranda, Schippers, Emile F., Stegeman, Arjan, Tami, Adriana, Veldkamp, Karin Ellen, Visser, Hannah, Voss, Andreas, Wegdam-Blans, Marjolijn C. A., Wertheim, Heiman F. L., Wever, Peter C., Koopmans, Marion P. G., Kluytmans, Jan A. J. W., and Kluytmans-van den Bergh, Marjolein F. Q.

Published
2023
Full Text
View/download PDF

11. Th1-dominant cytokine responses in kidney patients after COVID-19 vaccination are associated with poor humoral responses

Author

den Hartog, Yvette, Malahe, S. Reshwan K., Rietdijk, Wim J. R., Dieterich, Marjolein, Gommers, Lennert, Geers, Daryl, Bogers, Susanne, van Baarle, Debbie, Diavatopoulos, Dimitri A., Messchendorp, A. Lianne, van der Molen, Renate G., Remmerswaal, Ester B. M., Bemelman, Frederike J., Gansevoort, Ron T., Hilbrands, Luuk B., Sanders, Jan-Stephan, GeurtsvanKessel, Corine H., Kho, Marcia M. L., Reinders, Marlies E. J., de Vries, Rory D., and Baan, Carla C.

Published
2023
Full Text
View/download PDF

13. The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses

Author

Föhse, Konstantin, Geckin, Büsra, Zoodsma, Martijn, Kilic, Gizem, Liu, Zhaoli, Röring, Rutger J., Overheul, Gijs J., van de Maat, Josephine, Bulut, Ozlem, Hoogerwerf, Jacobien J., ten Oever, Jaap, Simonetti, Elles, Schaal, Heiner, Adams, Ortwin, Müller, Lisa, Ostermann, Philipp Niklas, van de Veerdonk, Frank L., Joosten, Leo A.B., Haagmans, Bart L., van Crevel, Reinout, van Rij, Ronald P., GeurtsvanKessel, Corine, de Jonge, Marien I., Li, Yang, Domínguez-Andrés, Jorge, and Netea, Mihai G.

Published
2023
Full Text
View/download PDF

14. The role of interleukin-21 in COVID-19 vaccine–induced B cell–mediated immune responses in patients with kidney disease and kidney transplant recipients

Author

Abrahams, Alferso C., Baas, Marije C., Mattheussens, Wouter B., Philipsen, Ria H.L.A., Bouwmans, Pim, Hemmelder, Marc H., ten Dam, Marc A.G.J., Gommers, Lennert, Mourik, Djenolan van, Bogers, Susanne, van Dijk, Laura L.A., Standaar, Dorien, der Heiden, Marieke van, Adema, Yvonne M.R., Boer-Verschragen, Marieken J., Rots, Nynke, de Vries, Aiko P.J., Malahe, S. Reshwan K., Hartog, Yvette den, Rietdijk, Wim J.R., van Baarle, Debbie, de Kuiper, Ronella, Reijerkerk, Derek, Ras, Alicia M., Geers, Daryl, Diavatopoulos, Dimitri A., Messchendorp, A. Lianne, van der Molen, Renate G., Remmerswaal, Ester B.M., Bemelman, Frederike J., Gansevoort, Ron T., Hilbrands, Luuk B., Sanders, Jan-Stephan, GeurtsvanKessel, Corine H., Kho, Marcia M.L., de Vries, Rory D., Reinders, Marlies E.J., and Baan, Carla C.

Published
2023
Full Text
View/download PDF

15. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals

Author

Zaeck, Luca M., Lamers, Mart M., Verstrepen, Babs E., Bestebroer, Theo M., van Royen, Martin E., Götz, Hannelore, Shamier, Marc C., van Leeuwen, Leanne P. M., Schmitz, Katharina S., Alblas, Kimberley, van Efferen, Suzanne, Bogers, Susanne, Scherbeijn, Sandra, Rimmelzwaan, Guus F., van Gorp, Eric C. M., Koopmans, Marion P. G., Haagmans, Bart L., GeurtsvanKessel, Corine H., and de Vries, Rory D.

Published
2023
Full Text
View/download PDF

16. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial

Author

Tan, Ngoc H, Geers, Daryl, Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Boerma, Annemarie, Nijhof, Sander H, van Dort, Karel A, Koopmans, Marion P G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, van Baarle, Debbie, Zaeck, Luca M, GeurtsvanKessel, Corine H, de Vries, Rory D, and van der Kuy, P Hugo M

Published
2023
Full Text
View/download PDF

17. Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial

Author

Dulfer, Elisabeth A., Geckin, Büsra, Taks, Esther J.M., GeurtsvanKessel, Corine H., Dijkstra, Helga, van Emst, Liesbeth, van der Gaast – de Jongh, Christa E., van Mourik, Djenolan, Koopmans, Petra C., Domínguez-Andrés, Jorge, van Crevel, Reinout, van de Maat, Josephine S., de Jonge, Marien I., and Netea, Mihai G.

Published
2023
Full Text
View/download PDF

18. Highly Divergent SARS-CoV-2 Alpha Variant in Chronically Infected Immunocompromised Person

Author

Munnink, Bas B. Oude, Nijhuis, Roel H.T., Worp, Nathalie, Boter, Marjan, Weller, Babette, Verstrepen, Babs E., GeurtsvanKessel, Corine, Corsten, Maarten L., Russcher, Anne, and Koopmans, Marion

Subjects
Immunocompromised host -- Case studies, Health
Abstract

Persons with an immune deficiency can be infected with viral pathogens for a prolonged period. This occurrence has been reported for noroviruses (1) but also has been documented for SARS-CoV-2 [...]

Published
2022
Full Text
View/download PDF

19. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial

Author

Abrahams, Alferso C., Baas, Marije C., Bouwmans, Pim, ten Dam, Marc A.G.J., Gommers, Lennert, Standaar, Dorien, van der Heiden, Marieke, Adema, Yvonne M.R., Boer-Verschragen, Marieken J., Mattheussens, Wouter B., Philipsen, Ria H.L.A., van Mourik, Djenolan, Bogers, Susanne, van Dijk, Laura L.A., Rots, Nynke, Smits, Gaby, Kuijer, Marjan, Hemmelder, Marc H., Kho, Marcia M L, Messchendorp, A Lianne, Frölke, Sophie C, Imhof, Celine, Koomen, Vera JCH, Malahe, S Reshwan K, Vart, Priya, Geers, Daryl, de Vries, Rory D, GeurtsvanKessel, Corine H, Baan, Carla C, van der Molen, Renate G, Diavatopoulos, Dimitri A, Remmerswaal, Ester B M, van Baarle, Debbie, van Binnendijk, Rob, den Hartog, Gerco, de Vries, Aiko P J, Gansevoort, Ron T, Bemelman, Frederike J, Reinders, Marlies E J, Sanders, Jan-Stephan F, and Hilbrands, Luuk B

Published
2023
Full Text
View/download PDF

21. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: a randomized placebo-controlled trial

Author

Gharbharan, Arvind, Jordans, Carlijn, Zwaginga, Lisa, Papageorgiou, Grigorios, van Geloven, Nan, van Wijngaarden, Peter, den Hollander, Jan, Karim, Faiz, van Leeuwen-Segarceanu, Elena, Soetekouw, Robert, Lammers, Jolanda, Postma, Douwe, Kampschreur, Linda, Groeneveld, Geert, Swaneveld, Francis, van der Schoot, C. Ellen, Götz, Hannelore, Haagmans, Bart, Koopmans, Marion, Bogers, Susanne, Geurtsvankessel, Corine, Zwaginga, Jaap Jan, Rokx, Casper, and Rijnders, Bart

Published
2023
Full Text
View/download PDF

22. Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination

Author

Geers, Daryl, Sablerolles, Roos S.G., van Baarle, Debbie, Kootstra, Neeltje A., Rietdijk, Wim J.R., Schmitz, Katharina S., Gommers, Lennert, Bogers, Susanne, Nieuwkoop, Nella J., van Dijk, Laura L.A., van Haren, Eva, Lafeber, Melvin, Dalm, Virgil A.S.H., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Huckriede, Anke L.W., Sette, Alessandro, Grifoni, Alba, de Swart, Rik L., Koopmans, Marion P.G., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., and de Vries, Rory D.

Published
2023
Full Text
View/download PDF

25. Author Correction: A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection

Author

Li, Tingting, Cai, Hongmin, Yao, Hebang, Zhou, Bingjie, Zhang, Ning, van Vlissingen, Martje Fentener, Kuiken, Thijs, Han, Wenyu, GeurtsvanKessel, Corine H., Gong, Yuhuan, Zhao, Yapei, Shen, Quan, Qin, Wenming, Tian, Xiao-Xu, Peng, Chao, Lai, Yanling, Wang, Yanxing, Hutter, Cedric A. J., Kuo, Shu-Ming, Bao, Juan, Liu, Caixuan, Wang, Yifan, Richard, Audrey S., Raoul, Hervé, Lan, Jiaming, Seeger, Markus A., Cong, Yao, Rockx, Barry, Wong, Gary, Bi, Yuhai, Lavillette, Dimitri, and Li, Dianfan

Published
2022
Full Text
View/download PDF

26. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients

Author

Millat-Martinez, Pere, Gharbharan, Arvind, Alemany, Andrea, Rokx, Casper, Geurtsvankessel, Corine, Papageorgiou, Grigorios, van Geloven, Nan, Jordans, Carlijn, Groeneveld, Geert, Swaneveld, Francis, van der Schoot, Ellen, Corbacho-Monné, Marc, Ouchi, Dan, Piccolo Ferreira, Francini, Malchair, Pierre, Videla, Sebastian, García García, Vanesa, Ruiz-Comellas, Anna, Ramírez-Morros, Anna, Rodriguez Codina, Joana, Amado Simon, Rosa, Grifols, Joan-Ramon, Blanco, Julian, Blanco, Ignacio, Ara, Jordi, Bassat, Quique, Clotet, Bonaventura, Baro, Bàrbara, Troxel, Andrea, Zwaginga, Jaap Jan, Mitjà, Oriol, and Rijnders, Bart J. A.

Published
2022
Full Text
View/download PDF

27. Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome.

Author

Nouwen, Anouk E. M., Zaeck, Luca M., Schappin, Renske, Geers, Daryl, Gommers, Lennert, Bogers, Susanne, Dik, Willem A., Pasmans, Suzanne G. M. A., GeurtsvanKessel, Corine H., de Vries, Rory D., and Dalm, Virgil A. S. H.

Subjects
BOOSTER vaccines, VACCINE effectiveness, HAEMOPHILUS influenzae, STREPTOCOCCUS pneumoniae, POLYSACCHARIDES
Abstract

Background: Netherton syndrome (NS) is a rare, severe genetic skin disorder, currently classified as an inborn error of immunity (IEI) due to previously reported immune dysregulation. We recently reported the results of an immunological evaluation showing no evidence for a relevant B- and/or T-cell mediated immunodeficiency, but immune responses after vaccination were not evaluated in that study. Therefore, we evaluated immune responses to three vaccine platforms in adult NS patients to further investigate the presence of a clinically relevant B- and/or T-cell immunodeficiency. Methods: Vaccination responses in eight adult NS patients were assessed in a cross-sectional study performed between January and August 2022. Clinical patient data were retrospectively retrieved from electronic patient files. Immune responses to a polysaccharide Streptococcus pneumoniae vaccine (PPV23) and conjugate Haemophilus influenzae type b vaccine (ActHiB) were measured. SARS-CoV-2-specific (functional) antibody and T-cell responses following booster vaccination with an mRNA-based COVID-19 vaccine were compared to controls. Results: None of the included patients suffered from recurrent and/or severe infections that could be attributed to a B- and/or T-cell immunodeficiency. ActHiB induced immune responses were normal in 7/7 NS patients. PPV23 induced responses were absent in 1/7, diminished in 2/7, and normal in 4/7 patients. Levels of SARS-CoV-2-specific binding and neutralizing antibodies after mRNA-based COVID-19 booster vaccination in NS patients were comparable to controls. SARS-CoV-2-specific CD4 + T-cell responses were detectable in all NS patients. In contrast, SARS-CoV-2-specific CD8 + T-cell responses were detectable in only 2/6 NS patients. T-cell responses to a positive control antigen pool were comparable to controls. Conclusions: Vaccine-induced immune responses were detectable after polysaccharide, conjugate and mRNA-based vaccination in our cohort of NS patients. A spectrum of responsiveness to vaccine challenges was found, with the ranges of vaccine responses overlapping those demonstrated in healthy control populations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.

Author

Gangaev, Anastasia, van Sleen, Yannick, Brandhorst, Nicole, Hoefakker, Kelly, Prajapati, Bimal, Singh, Amrita, Boerma, Annemarie, van der Heiden, Marieke, Oosting, Sjoukje F., van der Veldt, Astrid A. M., Hiltermann, T. Jeroen N., GeurtsvanKessel, Corine H., Dingemans, Anne-Marie C., Smit, Egbert F., de Vries, Elisabeth G. E., Haanen, John B. A. G., Kvistborg, Pia, and van Baarle, Debbie

Subjects
T cells, CANCER chemotherapy, COVID-19 vaccines, CANCER cells, FLOW cytometry
Abstract

Introduction: Research has confirmed the safety and comparable seroconversion rates following SARS-CoV-2 vaccination in patients with solid cancers. However, the impact of cancer treatment on vaccine-induced T cell responses remains poorly understood. Methods: In this study, we expand on previous findings within the VOICE trial by evaluating the functional and phenotypic composition of mRNA-1273-induced T cell responses in patients with solid tumors undergoing immunotherapy, chemotherapy, or both, compared to individuals without cancer. We conducted an ELISpot analysis on 386 participants to assess spike-specific T cell responses 28 days after full vaccination. Further in-depth characterization of using flow cytometry was performed on a subset of 63 participants to analyze the functional phenotype and differentiation state of spike-specific T cell responses. Results: ELISpot analysis showed robust induction of spike-specific T cell responses across all treatment groups, with response rates ranging from 75% to 80%. Flow cytometry analysis revealed a distinctive cytokine production pattern across cohorts, with CD4 T cells producing IFNγ, TNF, and IL-2, and CD8 T cells producing IFNγ, TNF, and CCL4. Variations were observed in the proportion of monofunctional CD4 T cells producing TNF, particularly higher in individuals without cancer and patients treated with chemotherapy alone, while those treated with immunotherapy or chemoimmunotherapy predominantly produced IFNγ. Despite these differences, polyfunctional spike-specific memory CD4 and CD8 T cell responses were comparable across cohorts. Notably, immunotherapy-treated patients exhibited an expansion of spike-specific CD4 T cells with a terminally differentiated effector memory phenotype. Discussion: These findings demonstrate that systemic treatment in patients with solid tumors does not compromise the quality of polyfunctional mRNA-1273-induced T cell responses. This underscores the importance of COVID-19 vaccination in patients with solid cancers undergoing systemic treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19

Author

Raadsen, Matthijs P., Gharbharan, Arvind, Jordans, Carlijn C. E., Mykytyn, Anna Z., Lamers, Mart M., van den Doel, Petra B., Endeman, Henrik, van den Akker, Johannes P. C., GeurtsvanKessel, Corine H., Koopmans, Marion P. G., Rokx, Casper, Goeijenbier, Marco, van Gorp, Eric C. M., Rijnders, Bart J. A., and Haagmans, Bart L.

Published
2022
Full Text
View/download PDF

31. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

Author

Oosting, Sjoukje F, van der Veldt, Astrid A M, GeurtsvanKessel, Corine H, Fehrmann, Rudolf S N, van Binnendijk, Rob S, Dingemans, Anne-Marie C, Smit, Egbert F, Hiltermann, T Jeroen N, den Hartog, Gerco, Jalving, Mathilda, Westphal, Tatjana T, Bhattacharya, Arkajyoti, van der Heiden, Marieke, Rimmelzwaan, Guus F, Kvistborg, Pia, Blank, Christian U, Koopmans, Marion P G, Huckriede, Anke L W, van Els, Cecile A C M, Rots, Nynke Y, van Baarle, Debbie, Haanen, John B A G, and de Vries, Elisabeth G E

Published
2021
Full Text
View/download PDF

32. Scenarios of future mpox outbreaks among men who have sex with men: a modelling study based on cross-sectional seroprevalence data from the Netherlands, 2022

Author

Shamier, Marc C, primary, Zaeck, Luca M, additional, Götz, Hannelore M, additional, Vieyra, Bruno, additional, Verstrepen, Babs E, additional, Wijnans, Koen, additional, Welkers, Matthijs RA, additional, Hoornenborg, Elske, additional, van Cleef, Brigitte AGL, additional, van Royen, Martin E, additional, Jonas, Kai J, additional, Koopmans, Marion PG, additional, de Vries, Rory D, additional, van de Vijver, David AMC, additional, and GeurtsvanKessel, Corine H, additional

Published
2024
Full Text
View/download PDF

33. Functional properties of measles virus proteins derived from a subacute sclerosing panencephalitis patient who received repeated remdesivir treatments

Author

Schmitz, Katharina S., primary, Handrejk, Kim, additional, Liepina, Lelde, additional, Bauer, Lisa, additional, Haas, Griffin D., additional, van Puijfelik, Fabiënne, additional, Veldhuis Kroeze, Edwin J. B., additional, Riekstina, Marta, additional, Strautmanis, Jurgis, additional, Cao, Huyen, additional, Verdijk, Robert M., additional, GeurtsvanKessel, Corine H., additional, van Boheemen, Sander, additional, van Riel, Debby, additional, Lee, Benhur, additional, Porotto, Matteo, additional, de Swart, Rik L., additional, and de Vries, Rory D., additional

Published
2024
Full Text
View/download PDF

34. Clinical and Virological Outcome of Monoclonal Antibody Therapies Across Severe Acute Respiratory Syndrome Coronavirus 2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study

Author

Huygens, Sammy, primary, GeurtsvanKessel, Corine, additional, Gharbharan, Arvind, additional, Bogers, Susanne, additional, Worp, Nathalie, additional, Boter, Marjan, additional, Bax, Hannelore I, additional, Kampschreur, Linda M, additional, Hassing, Robert-Jan, additional, Fiets, Roel B, additional, Levenga, Henriette, additional, Afonso, Pedro Miranda, additional, Koopmans, Marion, additional, Rijnders, Bart J A, additional, and Oude Munnink, Bas B, additional

Published
2024
Full Text
View/download PDF

36. Use of a diagnostic Puumala virus real-time RT-PCR in an orthohantavirus endemic region in the Netherlands

Author

Geeraedts, Felix, Wevers, Mariska, Bosma, Froukje, Boer, Maria de, Brinkman, J. N., Delsing, Corine, GeurtsvanKessel, Corine, Rockx, Barry, van der Zanden, Adri, Laverman, Gozewijn D., Geeraedts, Felix, Wevers, Mariska, Bosma, Froukje, Boer, Maria de, Brinkman, J. N., Delsing, Corine, GeurtsvanKessel, Corine, Rockx, Barry, van der Zanden, Adri, and Laverman, Gozewijn D.

Abstract

Laboratory diagnosis of orthohantavirus infection is primarily based on serology. However, for a confirmedserological diagnosis, evaluation of a follow-up serum sample is essential, which is time consuming and causes delay. Real-time reverse transcription polymerase chain reaction (RT-PCR) tests, if positive, provide an immediate and definitivediagnosis, and accurately identify the causative agent, where the discriminative nature of serology is suboptimal. We re-evaluated sera from orthohantavirus-suspected clinical cases in the Dutch regions of Twente and Achterhoek from July 2014 to April 2016 for the presence of Puumala orthohantavirus (PUUV), Tula orthohantavirus (TULV), and Seoul orthohantavirus (SEOV) RNA. PUUV RNA was detected in 11% of the total number (n = 85) of sera tested, in 50% of sera positive for anti-PUUV/TULV IgM (n = 16), and in 1.4% of sera negative or indeterminate for anti-PUUV/TULV IgM (n = 69). No evidence was found for the presence of TULV or SEOV viral RNA. Based on these findings,we propose two algorithms to implement real-time RT-PCR testing in routine orthohantavirus diagnostics, which optimally provide clinicians with early confirmeddiagnoses and could prevent possible further invasive testing and treatment.

Published
2024

37. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters

Author

Zaeck, Luca M, Tan, Ngoc H, Rietdijk, Wim J R, Geers, Daryl, Sablerolles, Roos S G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Rugebregt, Sharona, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, Haagmans, Bart L, van Baarle, Debbie, Koopmans, Marion P G, van der Kuy, P Hugo M, GeurtsvanKessel, Corine H, de Vries, Rory D, Zaeck, Luca M, Tan, Ngoc H, Rietdijk, Wim J R, Geers, Daryl, Sablerolles, Roos S G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Rugebregt, Sharona, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, Haagmans, Bart L, van Baarle, Debbie, Koopmans, Marion P G, van der Kuy, P Hugo M, GeurtsvanKessel, Corine H, and de Vries, Rory D

Abstract

Waning antibody responses after COVID-19 vaccination combined with the emergence of the SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness. As a countermeasure, bivalent mRNA-based booster vaccines encoding the ancestral spike protein in combination with that of Omicron BA.1 or BA.5 were introduced. Since then, different BA.2-descendent lineages have become dominant, such as XBB.1.5, JN.1, or EG.5.1. Here, we report post-hoc analyses of data from the SWITCH-ON study, assessing how different COVID-19 priming regimens affect the immunogenicity of bivalent booster vaccinations and breakthrough infections (NCT05471440). BA.1 and BA.5 bivalent vaccines boosted neutralizing antibodies and T-cells up to 3 months after boost; however, cross-neutralization of XBB.1.5 was poor. Interestingly, different combinations of prime-boost regimens induced divergent responses: participants primed with Ad26.COV2.S developed lower binding antibody levels after bivalent boost while neutralization and T-cell responses were similar to mRNA-based primed participants. In contrast, the breadth of neutralization was higher in mRNA-primed and bivalent BA.5 boosted participants. Combined, our data further support the current use of monovalent vaccines based on circulating strains when vaccinating risk groups, as recently recommended by the WHO. We emphasize the importance of the continuous assessment of immune responses targeting circulating variants to guide future COVID-19 vaccination policies.

Published
2024

38. Primary Exposure to SARS-CoV-2 via Infection or Vaccination Determines Mucosal Antibody-Dependent ACE2 Binding Inhibition

Author

Fröberg, Janeri, Koomen, Vera J.C.H., Van Der Gaast-De Jongh, Christa E., Philipsen, Ria, Geurtsvankessel, Corine H., De Vries, Rory D., Baas, Marije C., Van Der Molen, Renate G., De Jonge, Marien I., Hilbrands, Luuk B., Huynen, Martijn A., Diavatopoulos, Dimitri A., Fröberg, Janeri, Koomen, Vera J.C.H., Van Der Gaast-De Jongh, Christa E., Philipsen, Ria, Geurtsvankessel, Corine H., De Vries, Rory D., Baas, Marije C., Van Der Molen, Renate G., De Jonge, Marien I., Hilbrands, Luuk B., Huynen, Martijn A., and Diavatopoulos, Dimitri A.

Abstract

Background: Mucosal antibodies play a critical role in preventing SARS-CoV-2 infections or reinfections by blocking the interaction of the receptor-binding domain (RBD) with the angiotensin-converting enzyme 2 (ACE2) receptor on the cell surface. In this study, we investigated the difference between the mucosal antibody response after primary infection and vaccination. Methods: We assessed longitudinal changes in the quantity and capacity of nasal antibodies to neutralize the interaction of RBD with the ACE2 receptor using the spike protein and RBD from ancestral SARS-CoV-2 (Wuhan-Hu-1), as well as the RBD from the Delta and Omicron variants. Results: Significantly higher mucosal IgA concentrations were detected postinfection vs postvaccination, while vaccination induced higher IgG concentrations. However, ACE2-inhibiting activity did not differ between the cohorts. Regarding whether IgA or IgG drove ACE2 inhibition, infection-induced binding inhibition was driven by both isotypes, while postvaccination binding inhibition was mainly driven by IgG. Conclusions: Our study provides new insights into the relationship between antibody isotypes and neutralization by using a sensitive and high-Throughput ACE2 binding inhibition assay. Key differences are highlighted between vaccination and infection at the mucosal level, showing that despite differences in the response quantity, postinfection and postvaccination ACE2 binding inhibition capacity did not differ.

Published
2024

39. Scenarios of future mpox outbreaks among men who have sex with men:a modelling study based on cross-sectional seroprevalence data from the Netherlands, 2022

Author

Shamier, Marc C., Zaeck, Luca M., Götz, Hannelore M., Vieyra, Bruno, Verstrepen, Babs E., Wijnans, Koen, Welkers, Matthijs R.A., Hoornenborg, Elske, van Cleef, Brigitte A.G.L., van Royen, Martin E., Jonas, Kai J., Koopmans, Marion P.G., de Vries, Rory D., van de Vijver, David A.M.C., GeurtsvanKessel, Corine H., Shamier, Marc C., Zaeck, Luca M., Götz, Hannelore M., Vieyra, Bruno, Verstrepen, Babs E., Wijnans, Koen, Welkers, Matthijs R.A., Hoornenborg, Elske, van Cleef, Brigitte A.G.L., van Royen, Martin E., Jonas, Kai J., Koopmans, Marion P.G., de Vries, Rory D., van de Vijver, David A.M.C., and GeurtsvanKessel, Corine H.

Abstract

Background: Following the 2022–2023 mpox outbreak, crucial knowledge gaps exist regarding orthopoxvirus-specific immunity in risk groups and its impact on future outbreaks. Aim: We combined cross-sectional seroprevalence studies in two cities in the Netherlands with mathematical modelling to evaluate scenarios of future mpox outbreaks among men who have sex with men (MSM). Methods: Serum samples were obtained from 1,065 MSM attending Centres for Sexual Health (CSH) in Rotterdam or Amsterdam following the peak of the Dutch mpox outbreak and the introduction of vaccination. For MSM visiting the Rotterdam CSH, sera were linked to epidemiological and vaccination data. An in-house developed ELISA was used to detect vaccinia virus (VACV)-specific IgG. These observations were combined with published data on serial interval and vaccine effectiveness to inform a stochastic transmission model that estimates the risk of future mpox outbreaks.Results: The seroprevalence of VACV-specific antibodies was 45.4% and 47.1% in Rotterdam and Amsterdam, respectively. Transmission modelling showed that the impact of risk group vaccination on the original outbreak was likely small. However, assuming different scenarios, the number of mpox cases in a future outbreak would be markedly reduced because of vaccination. Simultaneously, the current level of immunity alone may not prevent future outbreaks. Maintaining a short time-to-diagnosis is a key component of any strategy to prevent new outbreaks. Conclusion: Our findings indicate a reduced likelihood of large future mpox outbreaks among MSM in the Netherlands under current conditions, but emphasise the importance of maintaining population immunity, diagnostic capacities and disease awareness.

Published
2024

40. Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins:A Phase I/II Dose-Finding Study

Author

Huygens, Sammy, Preijers, Tim, Swaneveld, Francis H., Kleine Budde, Ilona, GeurtsvanKessel, Corine H., Koch, Birgit C.P., Rijnders, Bart J.A., Huygens, Sammy, Preijers, Tim, Swaneveld, Francis H., Kleine Budde, Ilona, GeurtsvanKessel, Corine H., Koch, Birgit C.P., and Rijnders, Bart J.A.

Abstract

Background and Objective: During the COVID-19 pandemic, trials on convalescent plasma (ConvP) were performed without preceding dose-finding studies. This study aimed to assess potential protective dosing regimens by constructing a population pharmacokinetic (popPK) model describing anti-SARS-CoV-2 antibody titers following the administration of ConvP or hyperimmune globulins (COVIg). Methods: Immunocompromised patients, testing negative for anti-SARS-CoV-2 spike antibodies despite vaccination, received a range of anti-SARS-CoV-2 antibodies in the form of COVIg or ConvP infusion. The popPK analysis was performed using NONMEM v7.4. Monte Carlo simulations were performed to assess potential COVIg and ConvP dosing regimens for prevention of COVID-19. Results: Forty-four patients were enrolled, and data from 42 were used for constructing the popPK model. A two-compartment elimination model with mixed residual error best described the Nab-titers after administration. Inter-individual variation was associated to CL (44.3%), V1 (27.3%), and V2 (29.2%). Lean body weight and type of treatment (ConvP/COVIg) were associated with V1 and V2, respectively. Median elimination half-life was 20 days (interquartile range: 17–25 days). Simulations demonstrated that even monthly infusions of 600 mL of the ConvP or COVIg used in this trial would not achieve potentially protective serum antibody titers for > 90% of the time. However, as a result of hybrid immunity and/or repeated vaccination, plasma donors with extremely high antibody titers are now readily available, and a > 90% target attainment should be possible. Conclusion: The results of this study may inform future intervention studies on the prophylactic and therapeutic use of antiviral antibodies in the form of ConvP or COVIg. Clinical trial registration number: NL9379 (The Netherlands Trial Register).

Published
2024

41. Functional properties of measles virus proteins derived from a subacute sclerosing panencephalitis patient who received repeated remdesivir treatments

Author

Schmitz, Katharina S., Handrejk, Kim, Liepina, Lelde, Bauer, Lisa, Haas, Griffin D., van Puijfelik, Fabienne, Veldhuis Kroeze, Edwin J. B., Riekstina, Marta, Strautmanis, Jurgis, Cao, Huyen, Verdijk, Robert M., Geurtsvankessel, Corine H., van Boheemen, Sander, van Riel, Debby, Lee, Benhur, Porotto, Matteo, de Swart, Rik L., de Vries, Rory D., Schmitz, Katharina S., Handrejk, Kim, Liepina, Lelde, Bauer, Lisa, Haas, Griffin D., van Puijfelik, Fabienne, Veldhuis Kroeze, Edwin J. B., Riekstina, Marta, Strautmanis, Jurgis, Cao, Huyen, Verdijk, Robert M., Geurtsvankessel, Corine H., van Boheemen, Sander, van Riel, Debby, Lee, Benhur, Porotto, Matteo, de Swart, Rik L., and de Vries, Rory D.

Abstract

Subacute sclerosing panencephalitis (SSPE) is a rare but fatal late neurological complication of measles, caused by persistent measles virus (MeV) infection of the central nervous system. There are no drugs approved for the treatment of SSPE. Here, we followed the clinical progression of a 5-year-old SSPE patient after treatment with the nucleoside analog remdesivir, conducted a post-mortem evaluation of the patient’s brain, and characterized the MeV detected in the brain. The quality of life of the patient transiently improved after the first two courses of remdesivir, but a third course had no further clinical effect, and the patient eventually succumbed to his condition. Post-mortem evaluation of the brain displayed histopathological changes including loss of neurons and demyelination paired with abundant presence of MeV RNA-positive cells throughout the brain. Next-generation sequencing of RNA isolated from the brain revealed a complete MeV genome with mutations that are typically detected in SSPE, characterized by a hypermutated M gene. Additional mutations were detected in the polymerase (L) gene, which were not associated with resistance to remdesivir. Functional characterization showed that mutations in the F gene led to a hyperfusogenic phenotype predominantly mediated by N465I. Additionally, recombinant wild-type-based MeV with the SSPE-F gene or the F gene with the N465I mutation was no longer lymphotropic but instead efficiently disseminated in neural cultures. Altogether, this case encourages further investigation of remdesivir as a potential treatment of SSPE and highlights the necessity to functionally understand SSPE-causing MeV.

Published
2024

42. Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients:a multicenter prospective cohort study

Author

Huygens, Sammy, GeurtsvanKessel, Corine, Gharbharan, Arvind, Bogers, Susanne, Worp, Nathalie, Boter, Marjan, Bax, Hannelore I, Kampschreur, Linda M, Hassing, Robert-Jan, Fiets, Roel B, Levenga, Henriette, Afonso, Pedro Miranda, Koopmans, Marion, Rijnders, Bart J A, Oude Munnink, Bas B, Huygens, Sammy, GeurtsvanKessel, Corine, Gharbharan, Arvind, Bogers, Susanne, Worp, Nathalie, Boter, Marjan, Bax, Hannelore I, Kampschreur, Linda M, Hassing, Robert-Jan, Fiets, Roel B, Levenga, Henriette, Afonso, Pedro Miranda, Koopmans, Marion, Rijnders, Bart J A, and Oude Munnink, Bas B

Abstract

Background. Immunocompromised patients (ICPs) have an increased risk for a severe and prolonged COVID-19. SARS-CoV-2 monoclonal antibodies (mAbs) were extensively used in these patients, but data from randomized trials that focus on ICPs are lacking. We evaluated the clinical and virological outcome of COVID-19 in ICPs treated with mAbs across SARS-CoV-2 variants. Methods. In this multicenter prospective cohort study, we enrolled B-cell- and/or T-cell-deficient patients treated with casirivimab/imdevimab, sotrovimab, or tixagevimab/cilgavimab. SARS-CoV-2 RNA was quantified and sequenced weekly, and time to viral clearance, viral genome mutations, hospitalization, and death rates were registered. Results. Two hundred and forty five patients infected with the Delta (50%) or Omicron BA.1, 2, or 5 (50%) variant were enrolled. Sixty-seven percent were vaccinated; 78 treated as outpatients, of whom 2 required hospital admission, but both survived. Of the 159 patients hospitalized at time of treatment, 43 (27%) required mechanical ventilation or died. The median time to viral clearance was 14 days (interquartile range, 7-22); however, it took >30 days in 15%. Resistance-associated spike mutations emerged in 9 patients in whom the median time to viral clearance was 63 days (95% confidence interval, 57-69; P < .001). Spike mutations were observed in 1 of 42 (2.4%) patients after treatment with 2 active mAbs, in 5 of 34 (14.7%) treated with actual monotherapy (sotrovimab), and 3 of 20 (12%) treated with functional monotherapy (ie, tixagevimab/cilgavimab against tixagevimab-resistant variant). Conclusions. Despite treatment with mAbs, morbidity and mortality of COVID-19 in ICPs remained substantial. Combination antiviral therapy should be further explored and may be preferred in severely ICPs.

Published
2024

43. Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands

Author

Igloi, Zsofia, Velzing, Jans, van Beek, Janko, van de Vijver, David, Aron, Georgina, Ensing, Roel, Benschop, Kimberley, Han, Wanda, Boelsums, Timo, Koopmans, Marion, Geurtsvankessel, Corine, and Molenkamp, Richard

Subjects
Biosensors -- Evaluation, Immune system -- Testing, Molecular diagnostic techniques -- Evaluation, Health
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged >1 year ago (1) but still keeps a strong grip not only on daily life but also on diagnostic capacities. Reverse transcription [...]

Published
2021
Full Text
View/download PDF

44. Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study

Author

Hensley, Kathryn S., Jongkees, Marlou J., Geers, Daryl, GeurtsvanKessel, Corine H., Mueller, Yvonne M., Dalm, Virgil A. S. H., Papageorgiou, Grigorios, Steggink, Hanka, Gorska, Alicja, Bogers, Susanne, den Hollander, Jan G., Bierman, Wouter F. W., Gelinck, Luc B. S., Schippers, Emile F., Ammerlaan, Heidi S. M., van der Valk, Marc, van Vonderen, Marit G. A., Delsing, Corine E., Gisolf, Elisabeth H., Bruns, Anke H. W., Lauw, Fanny N., Berrevoets, Marvin A. H., Sigaloff, Kim C. E., Soetekouw, Robert, Branger, Judith, de Mast, Quirijn, Lammers, Adriana J. J., Lowe, Selwyn H., de Vries, Rory D., Katsikis, Peter D., Rijnders, Bart J. A., Brinkman, Kees, Roukens, Anna H. E., and Rokx, Casper

Subjects
Biological sciences
Abstract

Author(s): Kathryn S. Hensley, Marlou J. Jongkees, Daryl Geers, Corine H. GeurtsvanKessel, Yvonne M. Mueller, Virgil A. S. H. Dalm, Grigorios Papageorgiou, Hanka Steggink, Alicja Gorska, Susanne Bogers, Jan G. [...]

Published
2023
Full Text
View/download PDF

45. Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.

Author

Huygens, Sammy, GeurtsvanKessel, Corine, Gharbharan, Arvind, Bogers, Susanne, Worp, Nathalie, Boter, Marjan, Bax, Hannelore I, Kampschreur, Linda M, Hassing, Robert-Jan, Fiets, Roel B, Levenga, Henriette, Afonso, Pedro Miranda, Koopmans, Marion, Rijnders, Bart J A, and Munnink, Bas B Oude

Subjects
*THERAPEUTIC use of monoclonal antibodies, *T-cell lymphoma, *MORTALITY, *IMMUNIZATION, *RESEARCH funding, *VIRAL load, *PATIENTS, *IMMUNOCOMPROMISED patients, *HOSPITAL care, *HOSPITAL admission & discharge, *TREATMENT effectiveness, *DESCRIPTIVE statistics, *LONGITUDINAL method, *ANTIVIRAL agents, *RESEARCH, *ARTIFICIAL respiration, *GENETIC mutation, *COVID-19, *B cell lymphoma, *EVALUATION
Abstract

Background Immunocompromised patients (ICPs) have an increased risk for a severe and prolonged COVID-19. SARS-CoV-2 monoclonal antibodies (mAbs) were extensively used in these patients, but data from randomized trials that focus on ICPs are lacking. We evaluated the clinical and virological outcome of COVID-19 in ICPs treated with mAbs across SARS-CoV-2 variants. Methods In this multicenter prospective cohort study, we enrolled B-cell– and/or T-cell–deficient patients treated with casirivimab/imdevimab, sotrovimab, or tixagevimab/cilgavimab. SARS-CoV-2 RNA was quantified and sequenced weekly, and time to viral clearance, viral genome mutations, hospitalization, and death rates were registered. Results Two hundred and forty five patients infected with the Delta (50%) or Omicron BA.1, 2, or 5 (50%) variant were enrolled. Sixty-seven percent were vaccinated; 78 treated as outpatients, of whom 2 required hospital admission, but both survived. Of the 159 patients hospitalized at time of treatment, 43 (27%) required mechanical ventilation or died. The median time to viral clearance was 14 days (interquartile range, 7–22); however, it took >30 days in 15%. Resistance-associated spike mutations emerged in 9 patients in whom the median time to viral clearance was 63 days (95% confidence interval, 57–69; P <.001). Spike mutations were observed in 1 of 42 (2.4%) patients after treatment with 2 active mAbs, in 5 of 34 (14.7%) treated with actual monotherapy (sotrovimab), and 3 of 20 (12%) treated with functional monotherapy (ie, tixagevimab/cilgavimab against tixagevimab-resistant variant). Conclusions Despite treatment with mAbs, morbidity and mortality of COVID-19 in ICPs remained substantial. Combination antiviral therapy should be further explored and may be preferred in severely ICPs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Humoral and cellular immune responses after COVID-19 vaccination of lung transplant recipients and patients on the waiting list: a 6-month follow-up

Author

Hoek, Rogier A. S., primary, Liu, Siqi, additional, GeurtsvanKessel, Corine H., additional, Verschuuren, Erik A. M., additional, Vonk, Judith M., additional, Hellemons, Merel E., additional, Kool, Mirjam, additional, Wijbenga, Nynke, additional, Bogers, Susanne, additional, Scherbeijn, Sandra, additional, Rugebregt, Sharona, additional, van Gemert, Johanna P., additional, Steenhuis, Willie N., additional, Niesters, Hubert G. M., additional, van Baarle, Debbie, additional, de Vries, Rory D., additional, and Van Leer Buter, Coretta, additional

Published
2024
Full Text
View/download PDF

48. Uncovering a conserved vulnerability site in SARS‐CoV‐2 by a human antibody

Author

Li, Tingting, Cai, Hongmin, Zhao, Yapei, Li, Yanfang, Lai, Yanling, Yao, Hebang, Liu, Liu Daisy, Sun, Zhou, van Vlissingen, Martje Fentener, Kuiken, Thijs, GeurtsvanKessel, Corine H, Zhang, Ning, Zhou, Bingjie, Lu, Lu, Gong, Yuhuan, Qin, Wenming, Mondal, Moumita, Duan, Bowen, Xu, Shiqi, Richard, Audrey S, Raoul, Hervé, Chen, JianFeng, Xu, Chenqi, Wu, Ligang, Zhou, Haisheng, Huang, Zhong, Zhang, Xuechao, Li, Jun, Wang, Yanyan, Bi, Yuhai, Rockx, Barry, Chen, Junfang, Meng, Fei‐Long, Lavillette, Dimitri, and Li, Dianfan

Published
2021
Full Text
View/download PDF

49. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection

Author

Li, Tingting, Cai, Hongmin, Yao, Hebang, Zhou, Bingjie, Zhang, Ning, van Vlissingen, Martje Fentener, Kuiken, Thijs, Han, Wenyu, GeurtsvanKessel, Corine H., Gong, Yuhuan, Zhao, Yapei, Shen, Quan, Qin, Wenming, Tian, Xiao-Xu, Peng, Chao, Lai, Yanling, Wang, Yanxing, Hutter, Cedric A. J., Kuo, Shu-Ming, Bao, Juan, Liu, Caixuan, Wang, Yifan, Richard, Audrey S., Raoul, Hervé, Lan, Jiaming, Seeger, Markus A., Cong, Yao, Rockx, Barry, Wong, Gary, Bi, Yuhai, Lavillette, Dimitri, and Li, Dianfan

Published
2021
Full Text
View/download PDF

50. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Author

van Kampen, Jeroen J. A., van de Vijver, David A. M. C., Fraaij, Pieter L. A., Haagmans, Bart L., Lamers, Mart M., Okba, Nisreen, van den Akker, Johannes P. C., Endeman, Henrik, Gommers, Diederik A. M. P. J., Cornelissen, Jan J., Hoek, Rogier A. S., van der Eerden, Menno M., Hesselink, Dennis A., Metselaar, Herold J., Verbon, Annelies, de Steenwinkel, Jurriaan E. M., Aron, Georgina I., van Gorp, Eric C. M., van Boheemen, Sander, Voermans, Jolanda C., Boucher, Charles A. B., Molenkamp, Richard, Koopmans, Marion P. G., Geurtsvankessel, Corine, and van der Eijk, Annemiek A.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results